DSIP

    • DSIP

    DSIP is thought to enhance sleep regulation, reduce motor activity to improve deep sleep, stimulate adrenocorticotropic hormone (ACTH) and luteinizing hormone (LH) levels, and reportedly normalize blood pressure. DSIP can alter serum levels of certain hormones, such as ACTH, somatostatin, serotonin, and others.

    $55


    Contact us
    Category:

    DSIP Research Overview

    Delta Sleep-Inducing Peptide (DSIP) is a peptide with a molecular weight of 850 daltons. It has the amino acid motif: N-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-C. DSIP plays various roles, such as endocrine regulation, disease and medicine, and sleep induction. However, the connection between DSIP and sleep is not
    fully understood due to the lack of isolation of the DSIP gene, protein, and potential receptor.

    Research has been conducted on the effectiveness of DSIP in treating insomnia, pain, and withdrawal. DSIP has shown the ability to counteract opiate receptors, leading to a significant reduction in opioid and alcohol dependence. Clinical trials are currently underway to explore its potential in treating withdrawal syndrome. Additionally, DSIP has been found to alleviate narcolepsy and restore disrupted sleep patterns in certain studies


    DSIP Structure

    • delta Sleep-inducing peptide phosphate
    • 70754-23-3
    • (2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]acetyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]-3-phosphonooxypropanoyl]amino]acetyl]amino]pentanedioic acid
    • Dsip-P
    • delta sleep-inducing peptide, dihydrogen phosphate (ester)


    DSIP and Sleep Research

    Delta sleep-inducing peptide (DSIP) is a nonapeptide that was discovered in 1977 for its ability to stimulate slow or delta wave sleep. DSIP has been studied for its potential therapeutic effects on sleep and pain. Here are some key findings:

    • A study was conducted to examine the effects of DSIP on sleep in 16 patients with chronic insomnia. The findings revealed that DSIP led to improved sleep efficiency and reduced sleep latency compared to the placebo.
    • In a clinical pilot study, it was found that DSIP showed therapeutic benefits in individuals experiencing chronic and severe pain episodes. The study proposed that DSIP may have a regulatory or “programming” effect on the body’s natural opioid-peptidergic systems, both internally and externally within the brain.
    • Only one study has investigated the effects of DSIP on sleep EEG in normal men and found only minor effects.
    • DSIP possesses various psychophysiological properties in addition to its ability to induce natural sleep.
    • Normal sleep patterns were restored in middle-aged and elderly individuals with chronic insomnia by the end of DSIP administration. These improvements were sustained during the follow-up period.

    DSIP and Pain Relief

    Research has indicated that DSIP has the potential to effectively reduce pain in patients experiencing chronic and severe pain episodes. In a clinical pilot study, DSIP was given intravenously for five consecutive days, followed by five injections every 48-72 hours. This treatment resulted in a significant reduction in pain levels for six out of seven patients suffering from migraine episodes, vasomotor headaches, chronic tinnitus, and psychogenic pain attacks. Furthermore, DSIP demonstrated pain-reducing effects in headache and other pain syndromes with peptidergic mechanisms.


    DSIP and Addiction and Withdrawal

    Delta sleep-inducing peptide (DSIP) is a neuropeptide that has been extensively researched for its potential therapeutic applications in treating withdrawal syndromes caused by alcohol and opiates. The basis for this therapeutic use of DSIP comes from various animal studies conducted by Tissot. These studies demonstrated that when DSIP was directly injected into the bulbo-mesencephalo-thalamic recruiting system, it induced slow-wave sleep accompanied by numerous spindles. Importantly, the sleep-inducing effect of DSIP was reversed by Naloxone, suggesting that DSIP may have an agonistic activity on opiate receptors. Therefore, DSIP holds promise as a potential treatment for withdrawal syndromes.
    DSIP was given intravenously to 107 inpatients who showed symptoms of alcohol or opiate withdrawal. The doctors and nurses evaluated the effects of the treatment. About 13% of patients in the first group and 22% in the second group were unable to complete the evaluation. In 97% of opiate addicts and 87% of alcoholics, the clinical symptoms improved or disappeared after receiving DSIP. However, anxiety took longer to decrease. Overall, opiate addicts required more DSIP injections and had a longer course of clinical symptoms compared to alcoholics. Most patients tolerated the DSIP treatment well, although a few reported experiencing headaches.